Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors
April 28, 2023 12:27 ET
|
Ultragenyx Pharmaceutical Inc.
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and...
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
May 17, 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy...
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III
December 01, 2021 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Distinguished Life Sciences Leaders to be Honored at CLSA's 2015 Pantheon DiNA Awards Ceremony
November 09, 2015 10:10 ET
|
California Life Sciences Association
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- California Life Sciences Association (CLSA), the leading voice to drive innovation for California's life sciences sector, today announced...